Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in Parkinsonian rats

Journal of the Neurological Sciences

Volumn 304, Issue 1-2, 2011, Pages 29-34

  Wang, Yanchun ^a,b   Xu, Hanlin ^b   Fu, Qin ^a   Ma, Rong ^a   Xiang, Jizhou ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUBEI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Dopaminergic neuron; Liposome; Oxidative stress; Parkinson's disease; Polygonum cuspidatum; Rat; Resveratrol; Substantia nigra

Indexed keywords

ANTIOXIDANT; LIPOSOME; POLYGONUM CUSPIDATUM EXTRACT; REACTIVE OXYGEN METABOLITE; RESVERATROL; RESVERATROL LIPOSOME; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CELL LEVEL; CELL LOSS; CIRCLING BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG EFFICACY; MALE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; POLYGONUM CUSPIDATUM; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; LIPOSOMES; MALE; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; POLYGONUM CUSPIDATUM; RATS; RATS, WISTAR; STILBENES; SUBSTANTIA NIGRA;

EID: 79953321373     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2011.02.025     Document Type: Article

References (25)

1. Abou-Sleiman PM, Muqit MM, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006;7:207-19. (Pubitemid 43292466)
2. Hald A, Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link? Exp Neurol 2005;193:279-90.
3. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-20. (Pubitemid 127696281)
4. Soleas GJ, Diamandis EP, Goldberg DM. Resveratrol: a molecule whose time has come? And gone? Clin Biochem 1997;30:91-113.
5. Surh Y. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res 1999;428:305-27. (Pubitemid 29389702)
6. Bastianetto S, Zheng WH, Quirion R. Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br J Pharmacol 2000;131:711-20.
7. Virgili M, Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, transresveratrol in rats. Neurosci Lett 2000;281:123-6. (Pubitemid 30125880)
8. Nicolini G, Rigolio R, Miloso M, Bertelli AA, Tredici G. Anti-apoptotic effect of transresveratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line. Neurosci Lett 2001;302:41-4. (Pubitemid 32244192)
9. Lee MK, Kang SJ, Poncz M, Song KJ, Park KS. Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp Mol Med 2007;39: 376-84. (Pubitemid 47037629)
10. Walle T, Hsieh F, DeLegge MH, Oatis Jr JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004;32: 1377-82. (Pubitemid 39564557)
11. Xu HL, Fu YH, Gao P, Xu CJ. Extraction and isolation of resveratrol from polygonum cuspidatum. Lishizhen Med Materia Med Res 2006;17:1424-5.
12. Xu HL, Zhang N, Liu H, Cheng GM, Huang J. Preparation of resveratrol liposome. Hubei J Trad Chin Med 2009;31:55-6.
13. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973;20:415-55.
14. Lee DW, Andersen JK. Iron elevations in the aging Parkinsonian brain: a consequence of impaired iron homeostasis? J Neurochem 2010;112:332-9.
15. Pirkevi C, Lesage S, Brice A, Basak AN. From genes to proteins in Mendelian Parkinson's disease: an overview. Anat Rec (Hoboken) 2009;292:1893-901.
16. Olanow CW. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease. Mov Disord 1993;8(Suppl 1):S1-7.
17. Offen D, Ziv I, Panet H, Wasserman L, Stein R, Melamed E. Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2. Cell Mol Neurobiol 1997;17: 289-304. (Pubitemid 27251055)
18. Hastings TG. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995;64:919-24.
19. Jellinger K, Kienzl E, Rumpelmair G, Riederer P, Stachelberger H, Ben-Shachar D. Neuromelanin and nigrostriatal dopamine neuron degeneration. J Neurochem 1993;60:1976-7. (Pubitemid 23127613)
20. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992;59:1609-23.
21. Lotharius J, Brundin P. Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 2002;3:932-42.
22. Karlsson J, Emgard M, Brundin P, Burkitt MJ. Trans-resveratrol protects embryonic mesencephalic cells from tert-butyl hydroperoxide: electron paramagnetic resonance spin trapping evidence for a radical scavenging mechanism. J Neurochem 2000;75:141-50. (Pubitemid 30418179)
23. Sinha K, Chaudhary G, Gupta YK. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci 2002;71: 655-65.
24. Rotondo S, Rajtar G, Manarini S, Celardo A, Rotillo D, de Gaetano G. Effect of transresveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmacol 1998;123:1691-9. (Pubitemid 28182053)
25. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet 1993;341:1103-4. (Pubitemid 23114451)